Open an account

Prelude Therapeutics

PRLD · NASDAQ

$3.53+$0.14 (+4.13%)TodayMarket closed ·
Prev close $3.39

About PRLD

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 79 full-time employees. The company went IPO on 2020-09-25. By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, it has developed a diverse pipeline consisting of multiple distinct programs, including kinases, targeted protein degraders, and degrader antibody conjugates. PRT12396 its lead, mutant-selective JAK2V617F inhibitor, is an open-label and multi-center study in patients with high-risk polycythemia vera and intermediate and high-risk myelofibrosis. JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms. The firm has discovered and is developing a series of selective and orally bioavailable KAT6A selective degraders. KAT6A is engaged in treating advanced breast cancer & other solid tumors.

Employees
79
Headquarters
Wilmington, Delaware
Listed
Sep 25, 2020
Sector
Health Care
Industry
Biotechnology
Website
preludetx.com

PRLD key statistics

Market cap
281.71M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
552.75K
Volume
362.77K
Open price
$3.40
High today
$3.61
Low today
$3.35
52 Week high
$6.83
52 Week low
$1.16

Prelude Therapeutics (PRLD) at a glance

As of Oct 20, 2026, Prelude Therapeutics (PRLD) shares are priced at $3.53, giving the company a market cap of 281.71M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.35 and $3.61. The current price is 5.4% above the day's low and 2.2% below its high.

Volume so far is 362.77K shares, below the average of 552.75K shares a day.

Over the past year Prelude Therapeutics has ranged from $1.16 to $6.83, and now sits 42% of the way up that range.

Prelude Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.2006.

The average analyst price target is $8.67, 145.6% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 7 analystsAvg $8.67
Low
$6.06
Now
$3.53
High
$10.50

PRLD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 22.9% on average.

  1. Q3 FY24: reported -$0.43 per share against an estimate of -$0.4812
  2. Q4 FY24: reported -$0.38 per share against an estimate of -$0.4726
  3. Q1 FY25: reported -$0.42 per share against an estimate of -$0.4777
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.4483
  5. Q3 FY25: reported -$0.26 per share against an estimate of -$0.3726
  6. Q4 FY25: reported -$0.20 per share against an estimate of -$0.0296
  7. Q1 FY26: reported -$0.13 per share against an estimate of -$0.2533
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.2006

PRLD news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

  • Press releaseGlobe Newswire

    Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

  • Press releaseGlobe Newswire

    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD

  • Press releaseGlobe Newswire

    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Similar companies

Companies in the same industry as Prelude Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.